Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Research & Development (2023 - 2025)

Compass Therapeutics' Research & Development history spans 3 years, with the latest figure at $13.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 4.86% year-over-year to $13.7 million; the TTM value through Dec 2025 reached $56.0 million, up 32.17%, while the annual FY2025 figure was $56.0 million, 32.18% up from the prior year.
  • Research & Development for Q4 2025 was $13.7 million at Compass Therapeutics, up from $12.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $16.4 million in Q2 2025 and bottomed at $6.6 million in Q1 2023.
  • The 3-year median for Research & Development is $11.8 million (2023), against an average of $11.4 million.
  • The largest annual shift saw Research & Development decreased 2.48% in 2024 before it skyrocketed 48.87% in 2025.
  • A 3-year view of Research & Development shows it stood at $12.4 million in 2023, then increased by 4.93% to $13.0 million in 2024, then increased by 4.86% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Research & Development are $13.7 million (Q4 2025), $12.8 million (Q3 2025), and $16.4 million (Q2 2025).